City of Hope is initiating a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies.
The oncology field is confronting three forces simultaneously.
City of Hope opens first U.S. multicenter clinical trial for robotic single-port mastectomies for breast cancer patients
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
City of Hope broke ground on a new Pathology and Radiation Oncology Building designed to expand cancer treatment capacity and streamline care delivery in Los Angeles County.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
Top HHS officials last week called for a “moonshot” focused on the role of the microbiome in cancer.
FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively.
For years, clues pointed to the gut microbiome as a key factor in cancer treatment outcomes. Recent advances in gene sequencing are now clarifying its influence on how patients respond to therapy.
